Q1 Earnings Estimate for Immunic Issued By Leerink Partnrs

Key Points

• Leerink Partners estimates Immunic will report a Q1 2026 EPS of ($0.08), with a full-year consensus of ($0.94) EPS.
• The company recently missed its quarterly earnings expectation, reporting ($0.20) EPS compared to a consensus of ($0.18).
• Immunic's stock has an average target price of $7.50, with most analysts rating it as a buy or outperform.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Immunic in a report released on Thursday, August 7th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.05) EPS.

A number of other equities research analysts have also issued reports on the company. B. Riley reaffirmed a "buy" rating and issued a $5.00 price target (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. William Blair reaffirmed an "outperform" rating on shares of Immunic in a report on Friday, May 16th. Finally, D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Friday. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $7.50.

Immunic Trading Up 0.4%

IMUX traded up $0.00 on Monday, hitting $0.85. 1,302,725 shares of the company were exchanged, compared to its average volume of 1,148,710. The firm has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $0.97. Immunic has a twelve month low of $0.56 and a twelve month high of $2.11. The company has a market cap of $84.07 million, a price-to-earnings ratio of -0.69 and a beta of 1.39.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMUX. Invesco Ltd. acquired a new position in Immunic in the fourth quarter valued at $37,000. Barclays PLC purchased a new stake in shares of Immunic in the 4th quarter valued at about $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after purchasing an additional 96,894 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares during the period. Finally, Jane Street Group LLC grew its stake in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after buying an additional 152,726 shares during the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.